Alterations in NK cell subsets and the regulatory role of JAB1 in nasopharyngeal carcinoma with implications for tumor immunity and biomarker development
Blood NK cell patterns and a new marker outperform standard tumor tests for tracking nasopharyngeal cancer progression and treatment response.
Single-cell profiling of NPC patient samples identifies distinct NK cell subsets with opposing tumor-regulatory roles, and implicates JAB1 as a key regulator of NK cytotoxicity and an immunotherapy target. CD16+CD57+ NK cells in blood are prognostic, and JAB1/CD107a as NK biomarkers outperform conventional tumor markers SCC and CEA.
What the study was
- Study design
- RNA-seq + single-cell RNA-seq + functional assays + humanised mouse model
- Population
- Nasopharyngeal carcinoma (NPC) patients and mouse xenografts
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British journal of cancer
Why it surfaced
Novel NK cell biomarkers and immunotherapy target in NPC; British Journal of Cancer; preclinical/mixed species stage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.